ArticlePloS one2026
Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tailored B-cell monitoring in podocytopathies: a necessary shift in practice.Pediatric nephrology (Berlin, Germany) · 2026Article
- Comparative safety signals of carboplatin and cisplatin in lung cancer: a pharmacovigilance study based on FAERS.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgressive multifocal leukoencephalopathy (PML) is a rare, often fatal demyelinating disease caused by JC virus reactivation in immunocompromised patients. With the increasing use of immunosuppressants and biologics, PML reporting in non-HIV populations is rising. This study aimed to evaluate drug-associated PML reporting signals using real-world pharmacovigilance data.
methodsWe analyzed FAERS database from 2004Q1 to 2024Q4. We identified PML reports via MedDRA Terms and manual validation. Four algorithms (ROR, PRR, BCPNN, MGPS) were jointly applied, with drugs showing signals across all four defined as high-risk.
results7,244 PML reports involving 298 drugs were identified; 72 drugs showed consistent signals, predominantly immunomodulators (e.g., natalizumab, rituximab), antineoplastics, and biologics. High-risk indications included multiple sclerosis, lymphoma, autoimmune diseases, and organ transplantation. PML reporting increased substantially in non-HIV populations. Time-to -reporting varied widely (49-1343days). Over one-third of reports were associated with life-threatening outcomes or death.
conclusionsThis analysis identified 72 drugs with consistent PML reporting signals. However, these findings represent statistical associations in spontaneous reports, not causal relationships or true incidence rates. Inherent limitations-including underreporting, incomplete medication histories, and lack of exposure denominators-require cautious interpretation. Prospective validation studies are essential to establish causality and quantify absolute risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.